Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 3/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | OGG1 | O15527 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25500010 | 0.91 | HTR1B (0.43) | HTR1BALDH1A1KDM4EHPGDTDP1 | |
| Cg-200745 SCHEMBL16166645 | 0.90 | HTR1B (0.44) | HTR1BALDH1A1KDM4EHPGDTDP1 | |
| Cg-200745 SCHEMBL16166647 | 0.90 | HTR1B (0.44) | HTR1BALDH1A1KDM4EHPGDTDP1 | |
| Cg-200745 SCHEMBL29352975 | 0.90 | HTR1B (0.44) | HTR1BALDH1A1KDM4EHPGDTDP1 | |
| Cg-200745 SCHEMBL29761004 | 0.90 | HTR1B (0.44) | HTR1BALDH1A1KDM4EHPGDTDP1 | |
| Cg-200745 SCHEMBL29761007 | 0.89 | HTR1B (0.43) | HTR1BALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL1306561 | 0.88 | CNR2 (0.47) | HTR1BCNR2ALDH1A1KDM4EHPGD | |
| SCHEMBL1306558 | 0.88 | CNR2 (0.47) | HTR1BCNR2ALDH1A1KDM4EHPGD | |
| SCHEMBL1308955 | 0.88 | CNR2 (0.41) | HTR1BCNR2ALDH1A1KDM4EHPGD | |
| SCHEMBL1308954 | 0.88 | CNR2 (0.41) | HTR1BCNR2ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655207-B2 | Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same | CRYSTALGENOMICS, INC. (KR) | 2023-05-23 | — | — | US | disclosed |
| US-11655207-B2 | Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same | CRYSTALGENOMICS, INC. (KR) | 2023-05-23 | — | — | US | disclosed |
| US-20200283371-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655207-B2 | Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same | DOHH, CYP51A1, ASAH2 | HTR1B 2869/4885CNR2 208/4885ALDH1A1 851/4885 |
| US-20200283371-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME | DOHH, CYP51A1, CYP46A1 | HTR1B 2625/4885CNR2 201/4885ALDH1A1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.